Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3894MR)

This product GTTS-WQ3894MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens; Chimeric
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ3894MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ909MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-221
GTTS-WQ13398MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PR-1594804
GTTS-WQ14145MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA aPCSK927
GTTS-WQ7062MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ12199MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MORAb-022
GTTS-WQ4348MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIW-8405
GTTS-WQ6672MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ4151MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BI-754091
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW